

## Teva Pharmaceuticals: Innovating for a Healthier Future

Teva Pharmaceuticals, a global leader in the pharmaceutical industry, is dedicated to improving the lives of patients through innovative healthcare solutions. With a rich history spanning over 120 years, Teva has established itself as the world's largest manufacturer of generic medicines, ensuring that quality healthcare is accessible to millions of people worldwide

At Teva Nederland, we are committed to fostering a dynamic and inclusive work environment where talents can thrive and make a meaningful impact. Our team is united by a shared purpose: to deliver life-changing treatments to patients in need. By joining Teva, you will be part of a global network of professionals who are passionate about advancing healthcare and making a difference in the lives of patients

With our 3 facilities in Haarlem, we are manufacturing life saving drugs/medications, collaborating closely with healthcare professionals to supply the best cure for patients and support other departments at local, regional and global levels through our European headquarter.

At Teva, you will have the chance to work on diverse projects, collaborate with Experts, and contribute to the development of innovative medicines that address unmet medical needs.

Our commitment to professional growth and development ensures that you will be supported and empowered to reach your full potential.

We are dedicated to sustainability and improving access to healthcare in underserved communities. Our initiative aims to create a healthier future for all, and we invite you to be part of this journey.

Meet our Team at stand 49 to learn more about the exciting career opportunities at Teva Nederland. Together, we can innovate for a healthier future and make a real difference in the lives of patients.

**Join Teva Pharmaceuticals – Where Your Career Meets Purpose.**

Check: [www.teva.nl/yourcareer/](http://www.teva.nl/yourcareer/)



## RIBOPRO and IPA Partner to Advance mRNA-Driven Antibody Discovery

RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies, announced a strategic collaboration with ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA"), a global leader in AI-powered antibody discovery and development. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO's advanced mRNA-based expression expertise with IPA's in silico and wet-lab antibody discovery capabilities.

The collaboration leverages RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery with IPA's advanced B-cell screening, single-cell analysis, and deep-learning AI-driven discovery workflows. Together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery.

### Transforming Antibody Discovery with mRNA Technology

The success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. By leveraging RIBOPRO's proprietary mRNA and LNP technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics.

"Partnering with ImmunoPrecise Antibodies enables us to push the boundaries of mRNA-based immunization for therapeutic antibody discovery," said Sander van Asbeck, CEO of RIBOPRO. "By integrating our expertise in mRNA design and nanoparticle delivery with IPA's cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics."

### Driving Innovation in AI-Powered Antibody Discovery

IPA's approach combines advanced AI-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. The integration of mRNA immunization into IPA's workflow is expected



## Surfix: Advancing Point-of-Care Diagnostics with Photonic Precision


Surfix is a Dutch MedTech company based at the Agro Businesspark in Wageningen. Founded in 2011 as a contract research organization specializing in nano-coatings, the company pivoted in 2021—following a successful seed investment round—to focus on building a scalable product.

Since then, Surfix has been on a mission to revolutionize point-of-care diagnostics through its innovative Photonic Diagnostic Platform: a multi-modal solution that delivers lab-level precision for protein detection, combined with the speed and ease of point-of-care testing (POCT).

The platform integrates advanced photonics and proprietary selective coating technologies with smart microfluidics to provide fast, highly accurate, and cost-effective diagnostics. It is particularly well-suited for detecting biomarkers at sensitivity levels beyond the reach of conventional POCTs—addressing a critical unmet need in healthcare. Potential applications range from infectious disease detection to chronic disease monitoring, aligning closely with the interests of major diagnostic players.

Progress has accelerated in Wageningen. Last year, two top-tier diagnostics companies conducted paid, blinded evaluations of Surfix's platform. Both reported excellent results and initiated larger follow-up studies. This year, one of those companies confirmed Surfix's exceptional sensitivity in blood plasma, achieving a detection limit of 1 picogram/mL for IL-6. The results were benchmarked against a state-of-the-art central lab system, validating the platform's lab-grade precision in a POCT format. The other partner co-prepared a major IHI grant application with Surfix.

Meanwhile, Surfix continues to scale its operations, with a sharp focus on key value inflection points. The company also accepts co-development projects for immunoassays, generating early revenues and fostering partnerships with leading diagnostics companies.



Surfix USPs: multiplex with broad dynamic range and beyond lab-level sensitivity.

